- Home
- AMAL vs SPRY Comparison
AMAL vs SPRY Comparison
Compare AMAL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- SPRY
- Stock Information
- Founded
- AMAL 1923
- SPRY 2015
- Country
- AMAL United States
- SPRY United States
- Employees
- AMAL N/A
- SPRY N/A
- Industry
- AMAL Commercial Banks
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- SPRY Health Care
- Exchange
- AMAL Nasdaq
- SPRY Nasdaq
- Market Cap
- AMAL 1.1B
- SPRY 1.1B
- IPO Year
- AMAL 2018
- SPRY N/A
- Fundamental
- Price
- AMAL $32.52
- SPRY $11.24
- Analyst Decision
- AMAL Buy
- SPRY Strong Buy
- Analyst Count
- AMAL 4
- SPRY 4
- Target Price
- AMAL $36.13
- SPRY $26.00
- AVG Volume (30 Days)
- AMAL 273.7K
- SPRY 1.2M
- Earning Date
- AMAL 01-23-2025
- SPRY 03-20-2025
- Dividend Yield
- AMAL 1.72%
- SPRY N/A
- EPS Growth
- AMAL 20.28
- SPRY N/A
- EPS
- AMAL 3.44
- SPRY N/A
- Revenue
- AMAL $304,285,000.00
- SPRY $2,568,000.00
- Revenue This Year
- AMAL N/A
- SPRY $68,783.34
- Revenue Next Year
- AMAL $13.99
- SPRY $503.87
- P/E Ratio
- AMAL $9.45
- SPRY N/A
- Revenue Growth
- AMAL 10.82
- SPRY 8460.00
- 52 Week Low
- AMAL $21.33
- SPRY $7.55
- 52 Week High
- AMAL $38.19
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- AMAL 35.30
- SPRY 37.72
- Support Level
- AMAL $34.95
- SPRY $11.58
- Resistance Level
- AMAL $37.26
- SPRY $12.43
- Average True Range (ATR)
- AMAL 1.15
- SPRY 0.72
- MACD
- AMAL -0.19
- SPRY -0.14
- Stochastic Oscillator
- AMAL 7.06
- SPRY 0.53
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers a range of products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.